The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Gabriele Greve(University of Freiburg), Michael Lübbert(University of Freiburg)
Cited by 71
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
|Blood|2014|400
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
|Journal of Clinical Oncology|2011|393
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
|Leukemia Research|2007|125